<DOC>
	<DOCNO>NCT01878461</DOCNO>
	<brief_summary>This study evaluate efficacy safety M518101 subject plaque psoriasis</brief_summary>
	<brief_title>Evaluate Efficacy Safety M518101 Subjects With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Who able willing give sign informed consent Who male female age 18 year old plaque psoriasis confirm Investigator . Who 20 % body surface area ( BSA ) afflict plaque Who neither pregnant breastfeeding , plan become pregnant study . Who history allergy vitamin D3 derivative preparation history relevant drug hypersensitivity . Who pregnant lactating . Who renal hepatic insufficiency , clinically significant cardiac , renal hepatic disease . Who deem eligible determined medical history , physical examination clinical laboratory safety test . Who clinically relevant history presence disease surgical history psoriasis likely affect conduct study Whose serum calcium level exceed upper limit reference range Who use investigational medicinal product and/or participate clinical study within 60 day randomization . Who treat systemic therapy within 30days randomization . Who treat biologics within 5 halflives biologics day randomization Who treat topical therapy within 14days day randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>